Bear,

the deadline for submission for ASN was September 4, which as we know is well before the Phase 3 data would be known to RVX.

In that case, what exactly will the title of their presentation tell us about what the Phase 3 results were?  Or is it just that the acceptance of RVX for late breaking clinical trial is good enough for now, that is cause enough for celebration?  The real deal will be when they present the data in the ASN conference?

Thanks